Click to open
Skip to content
HepHIV
HepHIV Conference
  • Home login
  • Programme
  • Speakers Corner
  • Privacy Policy
  • Eposters
  • Lobby
  • Home login
  • Programme
  • Speakers Corner
  • Privacy Policy
  • Eposters
  • Lobby

Channel 1 - English group Lobby Channel 2 - Russian

Technical tips:

Full screen: You may click to the square on the right side beside the audio in order to unable the full screen display modus.

 

Q&A and Polls on external device:
You may use your mobile phone/Tablet to actively participate to the meeting. Please scan the QR code below or type

https://app.sli.do/event/k2y0utbs


Please check the latest program at https://hephiv.provirtualmeeting.com/program/ we are streaming at CET time Zone (Paris)

If nothing happen we recommend to do the following:
Make sure to use either Chrome, Firefox or Safari as browser.

The player won´t start
Refresh your browser
Refresh your browser
Click play button (in middle and or bottom left)

Click play
Click play In the middle and / or bottom left of the player


Audio
Make sure the the audio is unmuted.
Can be found at bottom right on the player (left less volume – right more volume)

Q&A
During the presentation delegates may ask questions to the speakers with the Q&A panel function that may be discussed during the Q&A Session and click the send button

Polls
Will appear automatically on the main screen and on the right side of the panel.

Please bear in mind that you only have few seconds to vote. 

Go to Top
UMSA Library
N.TitleAction
1Document Sample

Click to Open

2Document Sample

Click to Open

3Document Sample

Click to Open

4Video Sample

Click to Open

5Video Sample

Click to Open

6Video Sample

Click to Open

1:1 meeting scheduling

Videos on Demand
Session NumberPresenterSessionPresentation titleAccess
OS-1Daniel Simões (mod.), Jürgen Rockstroh (mod.) Ricardo Baptista Leite, Dorthe RabenOpening Session Part 1 of the live transmission (OS)View Session
OS-2António Lacerda SalesOpening Session Welcome message from the Portuguese Minister of HealthView Session
OS-3John RyanOpening Session Welcome from the European Commission: The EU response on HIV, viral hepatitis, STIs and TB in the futureView Session
OS-4Andrea AmmonOpening Session Post-2020/Covid-19 and progress towards the SDG targets: Where are we ?View Session
OS-5Hans KlugeOpening Session ‘The changed landscape’ – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19View Session
OS-6Daniel Simões (mod.), Jürgen Rockstroh (mod.), Rui Portugal; Panel discussion feat. all speakers of the OSOpening Session Part 2 of the live transmission (OS)View Session
PS1-1C. LanePlenary Session 1Perspectives from the US National Institute of Allergy and Infectious Diseases of the National Institutes of HealthView Session
PS1-2A. SullivanPlenary Session 1Impact of the COVID-19 pandemic on linkage to and retention in care for HIV, hepatitis B and C and sexually transmitted infections in the WHO European RegionView Session
PS1-3C. KantwerkPlenary Session 1s.a.m Health: Germany’s first digital sexual health service is providing COVID-safe remote STI testing and counselling during the Covid-19 Pandemic and beyondView Session
PS1-4V. StanilevskiyPlenary Session 1Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and Sverdlovsk region, RussiaView Session
PS1-5B. CollinsPlenary Session 1European testing week: adaptation of testing services during the COVID-19 pandemicView Session
AS1-1L. CosmaroAbstract Driven Session 1RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STIView Session
AS1-2J. TaylorAbstract Driven Session 1An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and future online testing policyView Session
AS1-3C. AgustíAbstract Driven Session 1Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator conditions: a cluster randomized controlled trialView Session
AS1-4A. BasuAbstract Driven Session 1Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK’s COVID-19 lockdownView Session
PS2-1C. EstcourtPlenary Session 2“Prevention is hard, Combination is key” – Good example of HIV/STI combination prevention in ScotlandView Session
PS2-2P. HoffmannPlenary Session 2Combination disease prevention in prisons: a comprehensive programme in LuxembourgView Session
PS2-3G. de VriesPlenary Session 2Good example of TB combination prevention in NetherlandsView Session
PS2-4E. SmoutPlenary Session 2The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs) in EnglandView Session
PS3-1Raimonda MatulionytėPlenary Session 3Experiences in innovative testing approaches for HIV, hepatitis, STIs and TBView Session
CSMichel Kazatchkine (Moderator) Jürgen Rockstroh (Moderator), Cary James, Andrew Winter, Jens Lundgren, Nicole Seguy, Yazdan Yazdanpanah, Nikoloz Chkhartishvili, Paul Sommerfeld, Nikos Dedes, Ricardo Baptista LClosing SessionIntegrating disease areas and settingsView Session
PS3-2Maka DaneliaPlenary Session 3Integrated screening for TB, HIV and HCV at the primary healthcare levelView Session
PS3-3M. GogishviliPlenary Session 3Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: COBATEST Network 2017-2019View Session
PS3-4Robert HejzakPlenary Session 3Implementing self-test programmes during COVID-19View Session
AS2-1R. TeodorescuAbstract Driven Session 2Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three level HCV elimination strategyView Session
AS2-2S. Shirley-BeavanAbstract Driven Session 2Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global overviewView Session
AS2-3S. MazzilliAbstract Driven Session 2Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, ItalyView Session
AS2-4E. EmanuelAbstract Driven Session 2Blood-borne virus testing in people who inject drugs with a history of sex workView Session
AS2-5R. RigoniAbstract Driven Session 2HCV care for PWID in Europe - results from a civil society-led monitoringView Session
PS4-1Thomas SeylerPlenary Session 4Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: a European perspectiveView Session
PS4-2Otilia MardhPlenary Session 4New evidence on testing and linkage to care for PWIDsView Session
PS4-3Marios AtzemisPlenary Session 4Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemicView Session
PS4-4Fadi MerouehPlenary Session 4What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs?View Session
Eposter Library
Programme Day 2
View Fullscreen
Programme Day 1
View Fullscreen
Channel 1
Rate

Please give a rate

Comments to author

    Your Name (required)


    Your Email (required)




    Your subject


    Your comments to author


    Rating

    Please give a rate



    Dr. Begoña Bermejo

     

    Physician and medical doctor from the University of Cadiz. Medical oncologist at the Clinical University Hospital of Valencia and Biomedical Research institute INCLIVA
    Associate Professor of Medicine School at University of Valencia

    She develops her assistance and research work in the breast pathology unit. She has an extensive experience in clinical trials and research projects in the area of breast cancer.Member of the breast cancer research group at the Carlos III institute.Member of the board of GEICAM (Spanish Breast Cancer Research Group)

     

    Dr. Enrique Santas Olmeda

     

    Dr. Enrique Santas, MD, PhD,  is a cardiologist at the Hospital Clínico Universitario in Valencia (Spain). He is an active clinician and an emergent researcher, with a focus on heart failure and cardiac imaging. Currently, he is the director of the cardio-oncology program at his institution, dedicated to the cardiovascular health of patients undergoing cancer treatment as well as cancer survivors.

     

    Join a meeting